Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Labeling DNA Probes03:31

Labeling DNA Probes

9.3K
DNA probes are fragments of DNA labeled with a reporter tag to enable their detection or purification. The resulting labeled DNA probes can then hybridize to target nucleic acid sequences through complementary base-pairing, and may be used to recover or identify these regions.
Radioisotopes, fluorophores, or small molecule binding partners like biotin or digoxigenin, are the most widely used reporter tags for labeling DNA probes. These labels can be attached to the probe DNA molecule via...
9.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Species-specific regulation of necroptosis by STK38-dependent RIPK1 phosphorylation.

Cell death and differentiation·2026
Same author

A radiopharmaceutical enhances CAR T cells against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and TME remodeling.

Cell reports. Medicine·2026
Same author

A Hybrid Experimental and in silico Platform for ITPK1 Chemical Probe Discovery.

SLAS discovery : advancing life sciences R & D·2026
Same author

CD4<sup>+</sup> T cells impair tumor growth through IL-3 and TNF-dependent vascular damage.

Science (New York, N.Y.)·2026
Same author

Development of novel GPC2-directed radiotheranostics and CAR T cell therapy for neuroblastoma.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Interaction of Bacterial Histidine Phosphatase SixA With Phosphocarrier Protein NPr and Phosphohistidine Analogs.

Journal of molecular biology·2026

Related Experiment Video

Updated: Jan 16, 2026

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

1.1K

Biodistribution-Driven Discovery Identifies a Glycosidase-Cleavable Linker to Reprogram Radiotheranostics.

Woonghee Lee1, Sai Reddy Doda2, Kwamena E Baidoo1

  • 1Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health; Bethesda, MD 20895, USA.

Biorxiv : the Preprint Server for Biology
|September 26, 2025
PubMed
Summary
This summary is machine-generated.

New cleavable linkers improve radiopharmaceutical therapy (RPT) for advanced cancers. These linkers enhance tumor targeting and reduce kidney toxicity, offering a promising strategy for more effective cancer treatment with fewer side effects.

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.5K
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

9.2K

Related Experiment Videos

Last Updated: Jan 16, 2026

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

1.1K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.5K
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

9.2K

Area of Science:

  • Oncology
  • Radiopharmaceutical Chemistry
  • Molecular Imaging

Background:

  • Radiopharmaceutical therapy (RPT) is standard for advanced prostate cancer and neuroendocrine tumors (NETs), but cures are limited by normal tissue toxicity.
  • Enzyme-cleavable linkers offer a strategy to improve RPT's therapeutic index by targeting tumor-specific enzymes.

Purpose of the Study:

  • To design, synthesize, and evaluate novel cleavable linkers for DOTA-TATE, an RPT agent.
  • To assess the impact of cleavable linkers on tumor uptake, kidney retention, and therapeutic efficacy in preclinical models.

Main Methods:

  • Synthesized a series of DOTA-TATE analogs with diverse cleavable linkers.
  • Utilized 86Y-labeled agents for positron emission tomography (PET) imaging in murine neuroendocrine tumor models.
  • Conducted in vitro and in vivo enzyme cleavage studies.
  • Performed therapeutic efficacy studies using 225Ac-labeled agents.

Main Results:

  • Two cleavable linkers, DOTA-MVK(ε)-TATE and DOTA-β-Gal-TATE, reduced kidney retention compared to DOTA-TATE.
  • 86Y-DOTA-β-Gal-TATE showed enhanced tumor uptake and up to 10-fold improved tumor-to-kidney ratios.
  • Both 225Ac-labeled cleavable agents demonstrated therapeutic efficacy with improved survival and reduced toxicity.
  • 225Ac-DOTA-β-Gal-TATE exhibited notably lower nephrotoxicity.

Conclusions:

  • Cleavable linker chemistry is a viable strategy to enhance RPT agent pharmacokinetics and reduce toxicity.
  • DOTA-β-Gal-TATE represents a promising next-generation RPT agent with improved tumor targeting and safety profile.
  • This approach holds potential for broader application in developing improved radiopharmaceutical therapies.